Purpose: The purpose of this study was to investigate the ability and efficacy of inducing sonoporation in a clinical setting, using commercially available technology, to increase the patients' quality of life and extend the low Eastern Cooperative Oncology Group performance grade; as a result increasing the overall survival in patients with pancreatic adenocarcinoma. Methods: Patients were treated using a customized configuration of a commercial clinical ultrasound scanner over a time period of 31.5 min following standard chemotherapy treatment with gemcitabine. SonoVue R ultrasound contrast agent was injected intravascularly during the treatment with the aim to induce sonoporation. Results: Using the authors' custom acoustic settings, the authors' patients were able to undergo an increased number of treatment cycles; from an average of 9 cycles, to an average of 16 cycles when comparing to a historical control group of 80 patients. In two out of five patients treated, the maximum tumor diameter was temporally decreased to 80 ± 5% and permanently to 70 ± 5% of their original size, while the other patients showed reduced growth. The authors also explain and characterize the settings and acoustic output obtained from a commercial clinical scanner used for combined ultrasound microbubble and chemotherapy treatment. Conclusions: It is possible to combine ultrasound, microbubbles, and chemotherapy in a clinical setting using commercially available clinical ultrasound scanners to increase the number of treatment cycles, prolonging the quality of life in patients with pancreatic adenocarcinoma compared to chemotherapy alone. © 2013 American Association of Physicists in Medicine.
I. PURPOSE
Cancer is the world's second largest cause of death with over 7.6 × 10 6 deaths a year (21% of NCD deaths). 1 There are over 217 000 new cases of pancreatic cancer worldwide every year. 2 Pancreatic cancer is very difficult to treat due to its aggressive biology, late diagnosis, the encasement of large blood vessels, and the presence of metastasis. Hence, surgery is rarely an option. Chemotherapy produces modest responses but is not curative in this setting, mainly because its use is severely hampered by toxic effects to vital organs. As a result, the survival is very low. The mortality of the inoperable patients is 50% within 3 months and 90% within 12 months. 3, 4 Sonoporation is a novel method for noninvasive targeted drug and gene delivery. [5] [6] [7] [8] Sonoporation is defined as the transient formation of pores in cell membranes owing to ultrasound or a combination of ultrasound and microbubbles.
These pores range in size from several nanometers to several micrometers, [9] [10] [11] [12] allowing for increased drug uptake in highly targeted regions. [13] [14] [15] The acoustic parameters used for sonoporation showing increased cellular uptake of chemotherapeutics and genes vary from low-intensity diagnostic ultrasound [mechanical index (MI) < 0.3] (Refs. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] to high-intensity diagnostic ultrasound (MI > 1.0). 9, [30] [31] [32] [33] [34] Throughout literature, the acoustic settings used to induce sonoporation vary drastically, with a broad range of these settings showing improved drug and gene delivery. Several studies also show the effect of clinical diagnostic ultrasound in standard color-Doppler and Bmode imaging on cellular uptake. 19, 20 These studies, which made use of clinical diagnostic scanners, concluded that a larger duty cycle was necessary to increase the effect of sonoporation. It has been shown that the ideal settings to induce sonoporation are when shock-waves were not present, in order to sustain the microbubbles, and when the duty cycle is long enough, to excite the microbubbles in the targeted area without heating the surrounding tissue. 16 Furthermore, higher intensities correlating to cavitation and jetting result in increased cell death due to mechanical damage instead of (transient) sonoporation. 33, [35] [36] [37] As a result, there is no consensus on the exact ultrasound settings to be used for sonoporation. 38 For this reason, we aimed to use settings that matched our previous in vitro and in vivo work as much as possible, i.e., an in situ MI = 0.2, maximum duty cycle, and minimum shockwave generation in order to preserve the microbubbles. 7, 8, 23 To date, all sonoporation experiments have been done either in vitro or in animal models, hence the effect of sonoporation in humans is not truly known yet.
Ultrasound has been used as a tool in the clinic for many years, especially in transabdominal imaging. Specifically, the pancreas can easily be imaged ultrasonically. 39 In clinical ultrasonic imaging, ultrasound is combined with so-called ultrasound contrast agents to locate tumors. 40, 41 These agents consist of gas microbubbles encapsulated by elastic shells. 42 Using a clinical diagnostic scanner for combined imaging and treatment allows for precise acoustic field alignment ensuring that the correct ultrasound intensity reaches the target area.
In this study, we worked toward optimizing the ultrasonic settings for invoking sonoporation in the target region of a pancreatic tumor using a common commercial clinical ultrasound scanner without physical modifications.
II. METHODS
A clinical scanner was calibrated in a degassed water bath in order to map the beam profile and optimize the acoustic settings. After the chemotherapeutic dose was delivered, the clinical probe was positioned aiming directly at the pancreatic tumor and locked in place for 31.5 min. The probe was attached to a ball joint and was positioned near the upper abdomen. Stomach and intestine were avoided in all cases to ensure propagation only through soft tissue, to ensure delivery of the aimed ultrasound intensity at the desired area. Once the tumor was located the probe orientation was fine-tuned in order to locate the largest slice of the tumor and as much vasculature as possible, i.e., the feeding vessels. The probe was then locked in position until the completion of the treatment. The natural breathing motion aided the treatment as the ultrasound slice gently oscillated through the tumor. By visualizing the vasculature and tumor, it could be ensured that the microbubbles were being sonicated at the target. These vessels were then used as a reference point for future treatments. Nine doses of ultrasound contrast agent were intravenously injected over this time period to enhance the sonoporation effect. To evaluate the efficacy of the combined treatment, we compared the amount of chemotherapy cycles the patient was able to receive. Furthermore, the tumor size was measured over the course of the treatment cycles to monitor and compare the tumor growth.
II.A. Ultrasound scanner configuration
A GE LOGIQ 9 ultrasound scanner (GE Healthcare, Waukesha, WI) combined with a 4C curvilinear probe (GE Healthcare) was used for both diagnosis and therapy.
To calibrate and program the diagnostic scanner for the optimized therapeutic settings, the probe was locked in position in a custom-made 250-l 3D scanning tank, containing degassed water. A calibrated HGL-200 bullet-type hydrophone (Onda, Sunnyvale, CA) connected to a WaveJet 354a oscilloscope (Teledyne LeCroy SA, Geneva, Switzerland) was used to measure the acoustic signal. The scanning tank had a spatial resolution of 0.4 μm. For the calibration, a 200-μm resolution was used. AQUASONIC R ultrasound transmission gel (Parker Laboratories, Fairfield, NJ) was placed on the transducer transmission surface and the probe was subsequently covered using a latex ultrasound probe cover (Sheathing Technologies, Inc., Morgan Hill, CA) prior to submersion. The diagnostic scanner settings were modified in order to achieve a maximum duty cycle without completely degrading the image quality, in addition to having a linear acoustic signal. We aimed for minimal acoustic shockwaves and harmonics minimizing potential cavitation. The absence of nonlinear content was verified by visualizing the temporal extent of the pulses and performing a fast Fourier transform (FFT). 43 Multiple focal depths (from 2.8 to 8.4 cm) and different settings (varying gain, changing window size, etc.) were evaluated to ensure similar acoustic conditions in all cases. To calculate the in situ acoustic pressures and intensities, the inwater values were derated by 0.3 dB/MHz/cm, an approximation of soft tissue attenuation in accordance to FDA and IEC guidelines. 44, 45 The attenuation factor of 0.3 dB/MHz/cm is only valid for soft tissue. Hence, this calibration was representative for our clinical positioning for targeting the pancreas. Table I shows the ultrasound scanner settings used to perform the simultaneous observation and treatment of the pancreatic tumors. Skilled clinical sonographers were called upon to judge the image quality. As there are variations between patients, such as tumor depth and tissue attenuation, certain settings had to be adjusted to ensure the correct ultrasound intensity reached the required area while maintaining the image quality. The settings that were varied are labeled as patientdepending. The three settings that were adjusted prior to treatment were: the focal depth, image depth, and gain. The focal and image depths were adjusted in order to visualize and position the acoustic focus directly in the middle of the tumor. By doing so, we could ensure that the acoustic conditions the tumor received were as similar as possible in all patients. The gain is only applied after the received signal; hence, it did not affect the acoustic output. The gain simply allowed for a brighter image.
Once the probe was locked in position and the tumor was "targeted", no changes to the ultrasonic conditions were made.
The settings chosen resulted in acoustic conditions shown in Table II and beam profiles shown in Fig. 1 .
The beam profile showed formation of multiple foci in close proximity along the lateral direction merging to form 
It is assumed that this is the region where sonoporation occurred most efficiently. Figure 2 shows the pulse repetition pattern generated by these settings. The pulse was amplitude-modulated, consisting of five cycles (2.1 μs) every 210 μs corresponding to a 1% duty cycle (repetition rate optimized). The duty cycle is defined as the percentage of time that ultrasound is being generated. This was measured during the spatial calibration process, in the acoustic focus with the hydrophone, for the duration of the inverse of the frame rate. Due to synthetic aperture and contrast enhanced imaging, the pulse pattern at the focus was amplitude-modulated. 46, 47 This can be seen in the upper panel of Fig. 2 . The lower panel of Fig. 2 shows the time signal of a single pulse. The pulse is still relatively sine-shaped, thus the transfer function of the propagation path is linear. Minor nonlinear effects can be seen after the fourth cycle. This indicates that shockwave occurrence and therefore microbubble destruction is negligible.
A FFT of the acoustic signal is shown in Fig. 3 . The center frequency is 1.9 MHz. Using a −3-dB or FWHM cutoff, the bandwidth was measured to be 1.1 MHz; from 1.3 to 2.4 MHz. A second harmonic peak can be seen at 3.6 MHz due to the minor nonlinear effects. This peak was 11 dB lower than the primary peak.
These settings complied with current safety guidelines for clinical diagnostic imaging. 44, 48, 49 Figure 4 shows two images of pancreatic cancer in two separate patients captured using the sonoporation treatment settings.
II.B. Chemotherapeutic and microbubble dosage
The recommended chemotherapeutic protocol was followed. 50 This protocol dictates which patients are eligible for chemotherapy and the dosages that can be administered. It includes dosage reduction values depending on platelet and absolute granulocyte count. The chemotherapeutic used, gemcitabine (Gemzar R , Eli Lilly and Company, Indianapolis, IN) was administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks out of every 4 weeks. Our protocol used the Eastern Cooperative Oncology Group (ECOG) performance status as a measure of the clinical condition. 51 The ECOG performance status ranges from 0 to 5, where 0 denotes a "fully active patient able to carry on all predisease performance without restriction," and 5 denotes a "dead" patient. Chemotherapy was halted if the patient exceeded a grade of 2 that states the patient is "ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours." The ECOG guidelines can be considered as a measure of how "healthy" a patient is. We used the ECOG guidelines to monitor the effectiveness of the combined treatment, i.e., the longer a patient stays below an ECOG grade of 3, the more effective the treatment is considered.
A single treatment cycle is defined as a single infusion of chemotherapeutic followed by ultrasound and microbubble treatment. The week pause was not counted as a treatment cycle. Once the granulocyte or platelet count was permanently too low, or the patient surpassed an ECOG performance status grade of 2, no more treatment was administered.
Gemcitabine was administered by intravenous infusion at a dose of 1000 mg/m 2 over 30 min. The start of the chemotherapeutic delivery is defined as T = 0 min. During the last 10 min (T = 20 min) of chemotherapeutic delivery, diagnostic imaging was performed in standard abdominal imaging mode and the tumor was located. Here, the tumor dimensions were measured with ultrasonography. Once the tumor was located, a custom-made clamp was used to lock the probe in position and the clinical scanner was switched to therapeutic settings (Fig. 5) . As the maximum systemic concentration of the chemotherapeutic starts at the finish of delivery (T = 30 min), this was chosen as the initiation point for the ultrasound treatment. Clinically approved SonoVue R (Bracco Imaging Scandinavia AB, Oslo, Norway) ultrasound contrast agent was used as the microbubble for sonoporation. To ensure microbubbles were present throughout the whole treatment, 0.5 ml of contrast agent followed by 5 ml saline were injected every 3.5 min, i.e., at T = 30.0, 33.5, 37.0, 40.5, 44.0, 47.5, 51.0, 54.5, and 58.0 min. A single vial (4.5 ml) was used throughout each treatment. Treatment was stopped at T = 61.5 min. The total cumulated ultrasound treatment time was only 18.9 s. This time frame can be seen in Fig. 5(a) .
FIG. 4.
Images captured using customized sonoporation settings using a clinical ultrasound scanner. The dense vasculature in early arterial phase to the right of the main tumor (circled in the B-mode frame) can be seen in panel (a) . Panel (b) shows the dimensions of the main tumor, indicated by lines 1 and 2, using the sonoporation settings.
II.C. Measurement of disease and tumor progression
The primary measure for evaluating the effectiveness of the treatment was the amount of cycles the patient could undergo. The more treatment cycles the patient underwent, the longer the patient was considered healthy. the tumor size was reduced substantially in accordance to the Response Evaluation Criteria in Solid Tumors (RECIST), 52 the treatment modality was re-evaluated, e.g., transfer to radiation therapy or surgery. This was considered a successful treatment.
Diagnostic ultrasound imaging was performed weekly assessing the tumor size. As computerized tomography (CT) scans are considered the golden standard for following tumor growth, 53 every 8 weeks a CT scan was also performed to validate the tumor size. This value was used to follow the tumor progression.
Positron emission tomography (PET) imaging was also performed at the start of the treatment to assess the presence of metastasis. Figure 6 shows the pancreatic adenocarcinoma in patient 5 prior to ultrasound and microbubble treatment as seen by CT and PET imaging modalities.
II.D. Treatment group
Patients with inoperable pancreatic cancer and fulfilled the inclusion criteria at the Haukeland University Hospital, Bergen, Norway, who have volunteered to participate, were included. The inclusion criteria primarily stated that the patients must be >18 years of age, a diagnosis of inoperable pancreatic cancer, histologically verified, locally advanced (stage II/III) or metastatic (stage IV) adenocarcinoma of the pancreas, and must be ambulatory with an ECOG performance status between 0 and 2. For this case report, a total of five patients were recruited. Table III shows the characteristics of the five patients enrolled in this pilot study prior to treatment in addition to the start and end dates of the treatment for every patient.
II.E. Control group
Taking into account the guidelines for gemcitabine treatment, it can be deduced that the more treatment cycles the patient can undergo, the longer the patient can be considered healthy; hence, the more effective the treatment. Once the patient surpasses a Level 2 in the ECOG performance sta- tus guidelines, they would no longer receive treatment; this would accordingly define the end of the healthy and ambulatory period. Our control group consisted of 80 patients from 2009 to 2011 with histology showing pancreatic adenocarcinoma (matching the same criteria as our patients). These patients received the identical chemotherapy treatment (in accordance to Gemzar guidelines 50 ) at Haukeland University Hospital, Bergen, Norway. The control treatments were also discontinued once they surpassed an ECOG performance grade of 2 or their blood counts dropped below the chemotherapy guidelines. Patients who received a different treatment were excluded from the control group. The data were accessed through the internal hospital medical system. The same anonymous data will be available on the Norwegian national cancer registry. 
II.F. Ethical considerations
All experiments were performed with approval from the regional ethics committee under Reference No. 2011/1601/ REK vest.
III. RESULTS AND DISCUSSION
The beam characterization showed that the clinical scanner took into account the attenuation of soft tissue when varying the focal depth. This allowed for a good prediction of the ultrasound profile in situ and easy manipulation of the ultrasound intensity and positioning. The "active" area that we assume enhances the chemotherapy effect was long and wide in all cases independent of depth, surpassing the tumor size, allowing a maximum flexibility on treatment area. It has to be assumed that there are some fluctuations in the sound field pressures due to tissue property variations, but this should not drastically change the sound field in our case, as acoustic propagation was only through soft tissue. Taking into account the vast range of ultrasound intensities used to induce sonoporation, as seen in literature, we assume that sonoporation may be occurring at lower or higher acoustic pressures independent of the varying attenuation of tissue. A benefit of using a clinical probe is also that due to the synthetic aperture, objects obscuring the field of view do not affect the beam formation in other areas; hence, we can predict the ultrasound dose delivered to our target area.
The image generated using our customized treatment settings allowed easy identification of both microbubbles and tumors. Figure 4(a) shows clear signs of microbubble presence in the tumor vasculature and surrounding tissue. Figure 4(b) shows the dimensions of a pancreatic tumor indicating the ease of detecting and aligning the probe to the tumor using the modified settings. Figure 7 shows the normalized perfusion curve where the arrows indicate the contrast injection time, as measured by the clinical scanner during the first 13 min of ultrasound and microbubble treatment. A pseudosinusoidal perfusion curve can be seen. Throughout the whole treatment, we can see that there are always microbubbles present. By using this pseudocontinuous method, we can ensure that there are always microbubbles present without the added complexity of continuous infusion equipment.
Our control group, treated with the same chemotherapeutic protocol, received an average of 9 ± 6 treatment cycles. To date all patients participating in this trial have already surpassed this indicating the potential benefit of our combined treatment on a clinical scale with minimal changes to chemotherapy protocols. The patients enrolled in this clinical pilot study received an average of 16 ± 7 treatment cycles. Figure 8 and Table IV show the effect of our combined treatment on the tumor size. After 8 weeks two patients showed a tumor diameter reduction. Patient 1 had a temporary tumor reduction from 4.0 to 3.1 cm. The next CT image was taken 24 weeks later and showed a growth to 4.6 cm; an increase of 15% from the original tumor size after 32 weeks of treatment. In patient 2, the treatment resulted in a continuous tumor reduction over 16 weeks, a very rare response from chemotherapy alone. As a result of his increased health, after ten treatment cycles, he was removed from the clinical trial to undergo radiation therapy. As this patient was removed from the trial due to the success of the treatment, a lower number of total and average treatments was seen, reducing the apparent effectiveness of the treatment as a whole. It should be noted that none of the patients in the control group stopped treatment due to its success but on the contrary, due to their deterioration. Two patients showed slow tumor growth from the eighth week onward (patient 3 and patient 4). Patient 5 also had a biopsy verified primary tumor in the pancreas. This was surgically removed but reoccurred with a small tumor in the operation sight and a large metastasis. This indicated that the tumor was at a late stage of development hence a limited response could be expected from the chemotherapeutic. Nevertheless, this patient was also able to receive 11 cycles of treatment.
As pancreatic cancer is such an aggressive form of cancer, it is very uncommon to see any decrease in tumor growth from chemotherapy. Our aim was to improve quality of life, to extend the healthy period of life, and conclusively extend the patients survival. If the patient was "healthy" enough [welldefined state in both groups, ECOG performance status 0-2 (Ref. 51 )], they would be able to receive treatment for a longer period. In fact, as long as they are ambulatory and capable of all self-care, they are able to receive the treatment. Seeing a decrease in the primary tumor size was an added benefit to the increased number of treatment cycles and thereby the anticipated survival.
The addition of the sonoporation procedure following the standard chemotherapeutic protocol did not add any discomfort to the patients. All patients were very relaxed during the treatment to a state where they could comfortably sleep throughout the whole treatment.
In this study, we also aimed to show that it is possible to induce sonoporation in the clinic using existing commercial equipment, while fitting in the current safety regulations for the use of diagnostic ultrasound. In our previous work, we showed that a duty cycle of 40% was ideal for sonoporation. 7, 23 Here, we are using a duty cycle of 1%; hence, expecting a small effect of sonoporation. There are many ways to improve this method of therapy such as by increasing the duty cycle from 1% to 40% and introducing targeted microbubbles that could attach to specific cancer cells. 40 The efficacy of our combined treatment should be compared to the efficacy of the current golden standard, the chemotherapeutic gemcitabine alone, where the viability of the patient has been extended by approximately 1 month. 3, 4 IV. CONCLUSION Using a clinical diagnostic scanner for therapeutic purposes allows accurate acoustic field alignment ensuring that the desired ultrasound dose reaches the target area. This configuration allows simultaneous visualization of the microbubbles present while treating the pancreatic tumor. In this pilot study, we saw an extended treatment period when comparing to the control group. Furthermore, we did not notice any adverse side effects. Combined ultrasound, microbubble, and chemotherapeutic treatment could pave the way for a novel enhanced drug delivery pathway.
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